Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia Behling

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Journal of Magnetic Resonance Imaging : JMRI|February 23, 2017
Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET studyPaul Manning, Paul Murphy, Kang Wang, et al.
The New England Journal of Medicine|October 20, 2021
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver DiseaseArun J Sanyal, Mark L Van Natta, Jeanne Clark, et al.
Journal of Hepatology|August 16, 2022
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLDBeom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2022
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' replyDanielle Brandman, Marie Boyle, Stuart McPherson, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical TrialTarek Hassanein, Dean Tai, Chenghai Liu, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Nature Medicine|September 7, 2023
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitisArun J Sanyal, Sudha S Shankar, Katherine P Yates, et al.
JAMA Network Open|October 5, 2019
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseDavid E Kleiner, Elizabeth M Brunt, Laura A Wilson, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of Magnetic Resonance Imaging : JMRI|February 23, 2017
Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET studyPaul Manning, Paul Murphy, Kang Wang, et al.
The New England Journal of Medicine|October 20, 2021
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver DiseaseArun J Sanyal, Mark L Van Natta, Jeanne Clark, et al.
Journal of Hepatology|August 16, 2022
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLDBeom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2022
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' replyDanielle Brandman, Marie Boyle, Stuart McPherson, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical TrialTarek Hassanein, Dean Tai, Chenghai Liu, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Nature Medicine|September 7, 2023
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitisArun J Sanyal, Sudha S Shankar, Katherine P Yates, et al.
JAMA Network Open|October 5, 2019
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseDavid E Kleiner, Elizabeth M Brunt, Laura A Wilson, et al.
Pageof 9